TerminatedPhase 4

Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD).

Stopped: Sponsor's decision

United States19 participantsStarted 2021-10-14

Plain-language summary

The study will compare the effectiveness of Bezlotoxumab in individuals with active C. diff ( Clostridium difficile) infection who are diagnosed with Inflammatory Bowel Disease.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * \>18 years old * active CDI receiving therapy * diagnosis of IBD * and history of CDI. Exclusion Criteria: * \<18 years old * no IBD * no CDI * history of colectomy * history of preexisting congestive heart failure * pregnant or nursing women * TCP\<50 * past cardiac history.

What they're measuring

Number of Participants With Recurrent C. Diff Infection at 90 Days

Timeframe: 90 days

Number of Participants With Recurrent C. Diff Infection at 12 Months

Timeframe: 12 months

Number of Participants With Recurrent C. Diff Infection at 24 Months

Timeframe: 24 months

Trial details

NCT IDNCT04626947

SponsorDavid Binion, MD

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-04-24

Results submitted2025-04-04

View on ClinicalTrials.gov More Inflammatory Bowel Diseases trials